Adjuvant radiotherapy is a cornerstone of the SoC for GBM patients, and the intraoperative administration of FcRn-silenced IL-12Fc to residual tumor parenchyma, as has been demonstrated for intraparenchymal ICI administration, should be feasible7. Here, FCGRT is linked to glioblastoma.